Factsheet: AXA Framlington Biotech GBP Z Acc

Name
AXA Framlington Biotech GBP Z Acc
Manager
AXA Investment Managers UK Ltd
Type
Unit Trust
ISIN
GB00B784NS11
Sector
Specialist
Launched
16/04/2012
OCF
0.82 %
Risk Rating
4
3 Year Sharpe
0.18
3 Year Alpha
-2.29
Yield
0 %
Benchmark
NASDAQ Biotechnology TR USD
The objective is to provide long-term capital appreciation by investing principally in equity securities of companies in biotechnology, genomic and medical research industries worldwide.
Holding %
Biogen Inc 9.02 %
Celgene Corp 5.80 %
Alexion Pharmaceuticals Inc 5.55 %
Gilead Sciences Inc 5.49 %
Regeneron Pharmaceuticals Inc 4.70 %
Vertex Pharmaceuticals Inc 4.37 %
Amgen Inc 3.82 %
Incyte Corp 3.58 %
Biomarin Pharmaceutical Inc 3.31 %
Shire PLC 2.99 %
Region %
United States 88.00 %
Sector %
Healthcare 100.00 %
Name
AXA Investment Managers UK Ltd
Address
EC1A 7NX, London, United Kingdom
UCITS
Yes
Legal Structure
Unit Trust

Managers

Dani Saurymper
Joined 04/01/2015

Dani Saurymper joined AXA IM in April 2015 as Fund Manager for the AXA Framlington Health Fund. He joined from Barclays Capital where he was a senior equity research analyst covering European healthcare.

Linden Thomson
Joined 07/05/2012

Data provided by Morningstar.

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Money Observer and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Morningstar. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.